US20060020338A1 - Process for making silicone intraocular lens with blue light absorption properties - Google Patents

Process for making silicone intraocular lens with blue light absorption properties Download PDF

Info

Publication number
US20060020338A1
US20060020338A1 US11/235,441 US23544105A US2006020338A1 US 20060020338 A1 US20060020338 A1 US 20060020338A1 US 23544105 A US23544105 A US 23544105A US 2006020338 A1 US2006020338 A1 US 2006020338A1
Authority
US
United States
Prior art keywords
medical device
blue light
thermally treated
catalysts
silicone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/235,441
Inventor
Yu-Chin Lai
Dominic Ruscio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/235,441 priority Critical patent/US20060020338A1/en
Publication of US20060020338A1 publication Critical patent/US20060020338A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16Intraocular lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/14Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041Lenses
    • G02B1/043Contact lenses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/442Colorants, dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00Materials or treatment for tissue regeneration
    • A61L2430/16Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Definitions

  • the present invention relates to a process for making silicone intraocular lenses with blue light absorption properties. More particularly, the present invention relates to a process for reacting a silicone intraocular lens with an ethyleneically unsaturated yellow dye to produce an intraocular lens capable of blocking blue light.
  • intraocular lens Since the 1940's optical devices in the form of intraocular lens (IOL) implants have been utilized as replacements for diseased or damaged natural ocular lenses. In most cases, an intraocular lens is implanted within an eye at the time of surgically removing the diseased or damaged natural lens, such as for example, in the case of cataracts. For decades, the preferred material for fabricating such intraocular lens implants was poly(methyl methacrylate), which is a rigid, glassy polymer.
  • Softer, more flexible IOL implants have gained in popularity in more recent years due to their ability to be compressed, folded, rolled or otherwise deformed. Such softer IOL implants may be deformed prior to insertion thereof through an incision in the cornea of an eye. Following insertion of the IOL in an eye, the IOL returns to its original pre-deformed shape due to the memory characteristics of the soft material. Softer, more flexible IOL implants as just described may be implanted into an eye through an incision that is much smaller, i.e., less than 4.0 mm, than that necessary for more rigid IOLs, i.e., 5.5 to 7.0 mm.
  • a larger incision is necessary for more rigid IOL implants because the lens must be inserted through an incision in the cornea slightly larger than the diameter of the inflexible IOL optic portion. Accordingly, more rigid IOL implants have become less popular in the market since larger incisions have been found to be associated with an increased incidence of postoperative complications, such as induced astigmatism.
  • Mazzocco U.S. Pat. No. 4,573,998 discloses a deformable intraocular lens that can be rolled, folded or stretched to fit through a relatively small incision. The deformable lens is inserted while it is held in its distorted configuration, then released inside the chamber of the eye, whereupon the elastic property of the lens causes it to resume its molded shape.
  • suitable materials for the deformable lens Mazzocco discloses polyurethane elastomers, silicone elastomers, hydrogel polymer compounds, organic or synthetic gel compounds and combinations thereof.
  • Soft, foldable, high refractive index, silicone intraocular lenses (IOLs) capable of absorbing blue light are prepared in accordance with the present invention through a coating process using a reactive yellow dye solution having blue light blocking properties.
  • the blue light absorbing IOLs produced in accordance with the present invention protect an eye's retina from potentially damaging blue light and thereby possibly providing protection from macular degeneration.
  • Blue light blocking silicone IOLs of the present invention are produced by exposing a semi-finished silicone IOL to an ethyleneically unsaturated yellow dye-containing solution and allowing the same to undergo a hydrosilation reaction. Such production process yields silicone IOLs with blue light absorbing properties. By absorbing blue light, the IOL serves to block blue light from reaching and potentially damaging the retina of an eye implanted with the IOL. Silicone IOLs so produced are transparent, relatively high in elongation and relatively high in refractive index.
  • Another object of the present invention is to provide a process for the production of silicone IOLs having relatively high refractive indices and good clarity.
  • Another object of the present invention is to provide a process for the production of silicone IOLs that are flexible.
  • Still another object of the present invention is to provide biocompatible silicone IOLs capable of absorbing blue light.
  • the present invention relates to a novel process for the production of high refractive index silicone IOLs capable of absorbing blue light and thereby blocking blue light from reaching the retina of an eye implanted with the IOL.
  • Silicone IOLs of the present invention are produced by allowing a semi-finished silicone IOL to react with an ethyleneically unsaturated dye through a hydrosilation reaction.
  • the subject process for treating silicone IOLs is relatively simple and produces biocompatible silicone IOLs capable of absorbing blue light.
  • a “semi-finished” silicone IOL for purposes of the present invention is a silicone IOL having free hydrosilyl groups.
  • a semi-finished silicone IOL in a weak solvent, such as for example but not limited to methylene chloride, containing a one or more reactive dyes, such as a reactive yellow dye, and one or more platinum catalysts, followed by thermal treatment of the IOL in an oven at a low temperature, preferably less than approximately 100° C. for a relatively short period of time, preferably less than several hours and more preferably less than approximately 30 minutes, a quantitative amount of dye can be incorporated into or coat the IOL.
  • a weak solvent such as for example but not limited to methylene chloride
  • a one or more reactive dyes such as a reactive yellow dye
  • platinum catalysts platinum catalysts or catalyst systems suitable for the hydrosilation reaction of the present invention, depending on the reaction temperature and kinetics desired.
  • platinum (3 to 3.5%)-divinyltetramethyldisiloxane complex is suitable for use in a room temperature reaction.
  • Platinum (3 to 3.5%)-cyclovinylmethylsiloxane complex is suitable for use in a reaction at a moderate temperature of 50 to 100° C.
  • the reaction kinetics can be regulated through the concentration of the catalyst and through the addition of various amounts of one or more inhibitors.
  • Suitable inhibitors include for example but are not limited to 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane. Such inhibitors may be present in the catalyst complex.
  • Reaction Scheme 1 Si—H represents the free hydrosilyl groups of a “semi-finished” silicone IOL, and H 2 C ⁇ CR 1 R 2 represents a reactive yellow dye.
  • R 1 can be H or CH 3 and R 2 is a group containing other functional groups as well as functional groups responsible for yellow color.
  • the reactive yellow dye can have for example, but is not limited to the following ethylenically unsaturated groups: vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene, nitrile and the like.
  • the reactive yellow dye can penetrate into the polymer matrix of the lens body, as well as, partially or completely coat the lens surface.
  • Reactive dyes useful in the manufacture of flexible, high refractive index silicone IOLs capable of absorbing blue light may be prepared through a process of multiple chemical reaction steps.
  • This process includes a step for forming a blue light absorbing functional group, i.e., a dye, such as for example but not limited to a diazo coupling for azo dye formation.
  • the process also includes a step to incorporate the compound with a dye functional group and a reagent that is ethylenically unsaturated.
  • a reactive azo yellow dye having two ethylenically unsaturated groups can be prepared by reacting a yellow dye having two alcohol groups with an acid chloride or an isocyanate having an ethylenically unsaturated group.
  • a reactive yellow dye with one ethylenically unsaturated group useful in accordance with the present invention such as for example but not limited to N-2-[3′-(2′′-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide, represented below in Formula 1, can be prepared by first reacting vinylacetyl chloride with 4-aminoethylphenol to give 4-vinylacetamidoethyl phenol, which is then coupled with the diazonium salt of toluidine as described in more detail below in Example 4.
  • N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline is accomplished by coupling the diazonium salt of aniline with N-phenyl diethanolamine.
  • a detailed procedure is also described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, incorporated herein in its entirety by reference.
  • the contents are chilled with an ice bath.
  • 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes.
  • the ice bath is then removed and the contents are continuously stirred overnight.
  • the mixture is then filtered and then condensed using a rotavapor.
  • HPLC analysis indicates only one major product.
  • the product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent.
  • the product is identified by NMR and Mass Spectroscopy.
  • N-2-[3′-(2′′-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide can be made in two steps.
  • the first step is the formation of 4-vinylacetamidoethyl phenol.
  • the second step is the coupling of azonium salt of toluidine with the phenol to give the product.
  • Step 1 Synthesis of 4-vinylacetamidoethyl phenol.
  • Step 2 Coupling of product from Step 1 with toluidine diazonium salt.
  • Model L161 U lenses are silicone IOLs derived from components consisting of a vinyl terminated polydimethyl-co-diphenyl siloxane, silicon-based reinforcing resins with vinyl groups, and an oligomer with multi hydrosilane units. Model L161 U silicone lenses have excess free hydrosilane groups after curing.
  • UV UV
  • visible absorption spectroscopy of coated lenses before and after processing.
  • Conditions, which give about or less than 50% transmittance and maintenance of lens power/cosmetics are chosen for further coating studies, followed by optimization of conditions.
  • Suitable catalysts for use in the process of the present invention include but are not limited to platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
  • the silicone IOLs produced as described herein have the flexibility required to allow the same to be folded or deformed for insertion into an eye through the smallest possible surgical incision, i.e., 3.5 mm or smaller. It is unexpected that the subject silicone IOLs described herein could possess the ideal physical properties disclosed herein. The ideal physical properties of the subject silicone IOLs are unexpected because changes in mechanical properties such as modulus, percent elongation and tear strength can occur upon addition of the reactive dye functional groups.
  • Silicone IOLs treated using the process of the present invention can be of any design capable of being rolled or folded for implantation through a relatively small surgical incision, i.e., 3.5 mm or less.
  • Such IOLs may be manufactured to have an optic portion and haptic portions made of the same or differing materials. Once the material(s) are selected, the same may be cast in molds of the desired shape, cured and removed from the molds. After such molding, the IOLs are treated in accordance with the process of the present invention and then cleaned, polished, packaged and sterilized by customary methods known to those skilled in the art.
  • the process of the present invention is also suitable for use in the production of other medical or ophthalmic devices such as contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays, corneal rings and like devices.
  • Silicone IOLs manufactured using the process of the present invention are used as customary in the field of ophthalmology.
  • a surgical cataract procedure an incision is placed in the cornea of an eye. Through the corneal incision the cataractous natural lens of the eye is removed (aphakic application) and an IOL is inserted into the anterior chamber, posterior chamber or lens capsule of the eye prior to closing the incision.
  • the subject ophthalmic devices may likewise be used in accordance with other surgical procedures known to those skilled in the field of ophthalmology.

Abstract

A process for producing silicone intraocular lenses (IOLs) capable of absorbing blue light. Intraocular lenses so produced block blue light from reaching the retina of an eye implanted with the IOL. By blocking blue light from reaching the retina, the IOL thereby prevents potential damage to the retina.

Description

    CROSS-REFERENCE OF RELATED APPLICATION
  • This application is a divisional of Ser. No. 10/657,781 filed Sep. 8, 2003.
  • FIELD OF THE INVENTION
  • The present invention relates to a process for making silicone intraocular lenses with blue light absorption properties. More particularly, the present invention relates to a process for reacting a silicone intraocular lens with an ethyleneically unsaturated yellow dye to produce an intraocular lens capable of blocking blue light.
  • BACKGROUND OF THE INVENTION
  • Since the 1940's optical devices in the form of intraocular lens (IOL) implants have been utilized as replacements for diseased or damaged natural ocular lenses. In most cases, an intraocular lens is implanted within an eye at the time of surgically removing the diseased or damaged natural lens, such as for example, in the case of cataracts. For decades, the preferred material for fabricating such intraocular lens implants was poly(methyl methacrylate), which is a rigid, glassy polymer.
  • Softer, more flexible IOL implants have gained in popularity in more recent years due to their ability to be compressed, folded, rolled or otherwise deformed. Such softer IOL implants may be deformed prior to insertion thereof through an incision in the cornea of an eye. Following insertion of the IOL in an eye, the IOL returns to its original pre-deformed shape due to the memory characteristics of the soft material. Softer, more flexible IOL implants as just described may be implanted into an eye through an incision that is much smaller, i.e., less than 4.0 mm, than that necessary for more rigid IOLs, i.e., 5.5 to 7.0 mm. A larger incision is necessary for more rigid IOL implants because the lens must be inserted through an incision in the cornea slightly larger than the diameter of the inflexible IOL optic portion. Accordingly, more rigid IOL implants have become less popular in the market since larger incisions have been found to be associated with an increased incidence of postoperative complications, such as induced astigmatism.
  • With recent advances in small-incision cataract surgery, increased emphasis has been placed on developing soft, foldable materials suitable for use in artificial IOL implants. Mazzocco, U.S. Pat. No. 4,573,998, discloses a deformable intraocular lens that can be rolled, folded or stretched to fit through a relatively small incision. The deformable lens is inserted while it is held in its distorted configuration, then released inside the chamber of the eye, whereupon the elastic property of the lens causes it to resume its molded shape. As suitable materials for the deformable lens, Mazzocco discloses polyurethane elastomers, silicone elastomers, hydrogel polymer compounds, organic or synthetic gel compounds and combinations thereof.
  • In recent years, blue light (400-500 nm) has been recognized as being potentially hazardous to the retina. Accordingly, yellow dyes to block blue light have been used in foldable intraocular lenses, in conjunction with ultraviolet light absorbers, to avoid potential damaging effects. Freeman et al., U.S. Pat. No. 6,353,069, disclose high refractive index copolymers comprising two or more acrylate and/or methacrylate monomers with aromatic groups. Ophthalmic devices made of the copolymers may also include colored dyes, such as the yellow dyes disclosed in U.S. Pat. No. 5,470,932. Such materials exhibit sufficient strength to allow devices made of them, such as intraocular lenses, to be folded or manipulated without fracturing.
  • Because of shortcomings in the properties of many soft, flexible materials used in the manufacture of ophthalmic devices, such as the formation of water vacuoles or “glistenings”, and low refractive index, which requires a lens to be relatively thick in order to provide a lens of proper refractive power, new materials and methods of manufacturing of ophthalmic devices are needed.
  • SUMMARY OF THE INVENTION
  • Soft, foldable, high refractive index, silicone intraocular lenses (IOLs) capable of absorbing blue light are prepared in accordance with the present invention through a coating process using a reactive yellow dye solution having blue light blocking properties. The blue light absorbing IOLs produced in accordance with the present invention protect an eye's retina from potentially damaging blue light and thereby possibly providing protection from macular degeneration.
  • Blue light blocking silicone IOLs of the present invention are produced by exposing a semi-finished silicone IOL to an ethyleneically unsaturated yellow dye-containing solution and allowing the same to undergo a hydrosilation reaction. Such production process yields silicone IOLs with blue light absorbing properties. By absorbing blue light, the IOL serves to block blue light from reaching and potentially damaging the retina of an eye implanted with the IOL. Silicone IOLs so produced are transparent, relatively high in elongation and relatively high in refractive index.
  • Accordingly, it is an object of the present invention to provide a process for the production of silicone IOLs capable of absorbing blue light.
  • Another object of the present invention is to provide a process for the production of silicone IOLs having relatively high refractive indices and good clarity.
  • Another object of the present invention is to provide a process for the production of silicone IOLs that are flexible.
  • Still another object of the present invention is to provide biocompatible silicone IOLs capable of absorbing blue light.
  • These and other objectives and advantages of the present invention, some of which are specifically described and others that are not, will become apparent from the detailed description and claims that follow.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to a novel process for the production of high refractive index silicone IOLs capable of absorbing blue light and thereby blocking blue light from reaching the retina of an eye implanted with the IOL. Silicone IOLs of the present invention are produced by allowing a semi-finished silicone IOL to react with an ethyleneically unsaturated dye through a hydrosilation reaction. The subject process for treating silicone IOLs is relatively simple and produces biocompatible silicone IOLs capable of absorbing blue light.
  • A “semi-finished” silicone IOL for purposes of the present invention, is a silicone IOL having free hydrosilyl groups. By dipping a semi-finished silicone IOL in a weak solvent, such as for example but not limited to methylene chloride, containing a one or more reactive dyes, such as a reactive yellow dye, and one or more platinum catalysts, followed by thermal treatment of the IOL in an oven at a low temperature, preferably less than approximately 100° C. for a relatively short period of time, preferably less than several hours and more preferably less than approximately 30 minutes, a quantitative amount of dye can be incorporated into or coat the IOL. There are several platinum catalysts or catalyst systems suitable for the hydrosilation reaction of the present invention, depending on the reaction temperature and kinetics desired. For example, platinum (3 to 3.5%)-divinyltetramethyldisiloxane complex is suitable for use in a room temperature reaction. Platinum (3 to 3.5%)-cyclovinylmethylsiloxane complex is suitable for use in a reaction at a moderate temperature of 50 to 100° C. The reaction kinetics can be regulated through the concentration of the catalyst and through the addition of various amounts of one or more inhibitors. Suitable inhibitors include for example but are not limited to 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane. Such inhibitors may be present in the catalyst complex. The chemical reaction that takes place as a result of this process is illustrated below in Reaction Scheme 1.
    Figure US20060020338A1-20060126-C00001

    As depicted above in Reaction Scheme 1, Si—H represents the free hydrosilyl groups of a “semi-finished” silicone IOL, and H2C═CR1R2 represents a reactive yellow dye. Here, R1 can be H or CH3 and R2 is a group containing other functional groups as well as functional groups responsible for yellow color. The reactive yellow dye can have for example, but is not limited to the following ethylenically unsaturated groups: vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene, nitrile and the like. Depending on the particular solvent and the concentration of reactive yellow dyes in the solvent, the reactive yellow dye can penetrate into the polymer matrix of the lens body, as well as, partially or completely coat the lens surface.
  • Reactive dyes useful in the manufacture of flexible, high refractive index silicone IOLs capable of absorbing blue light, may be prepared through a process of multiple chemical reaction steps. This process includes a step for forming a blue light absorbing functional group, i.e., a dye, such as for example but not limited to a diazo coupling for azo dye formation. The process also includes a step to incorporate the compound with a dye functional group and a reagent that is ethylenically unsaturated. For example, a reactive azo yellow dye having two ethylenically unsaturated groups can be prepared by reacting a yellow dye having two alcohol groups with an acid chloride or an isocyanate having an ethylenically unsaturated group. Such is depicted in Reaction Schemes 2 through 3 wherein a yellow dye, N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline (Solvent Yellow 58), synthesized in accordance with the procedure of Example 1 below, is used as an example not intended to be limiting.
    Figure US20060020338A1-20060126-C00002
  • Here, “Ph” represents either C6H5 or C6H4, as appropriate.
    Figure US20060020338A1-20060126-C00003

    Alternatively, a reactive yellow dye with one ethylenically unsaturated group useful in accordance with the present invention, such as for example but not limited to N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide, represented below in Formula 1,
    Figure US20060020338A1-20060126-C00004

    can be prepared by first reacting vinylacetyl chloride with 4-aminoethylphenol to give 4-vinylacetamidoethyl phenol, which is then coupled with the diazonium salt of toluidine as described in more detail below in Example 4.
  • The process of the present invention for preparing flexible, high refractive index silicone IOLs with blue light absorption properties is described in still greater detail in the Examples provided below.
  • EXAMPLE 1 Synthesis of N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline (Solvent Yellow 58)
  • The synthesis of N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline is accomplished by coupling the diazonium salt of aniline with N-phenyl diethanolamine. A detailed procedure is also described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, incorporated herein in its entirety by reference.
  • EXAMPLE 2 Synthesis of N,N-bis-(2-alivicarbamatoethyl)-(4′-phenylazo)aniline
  • A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.7 grams (0.02 mole) of N,N-bis-(2-hydroxyethyl)-(4-phenylazo)aniline, 3.28 g of allyl isocyanate (0.04 mole) (Aldrich Chemical, Inc., Milwaukee, Wis.) and 0.014 g of dibutyltin dilaurate (Aldrich Chemical). The mixture is heated and refluxed overnight under vigorous stirring. The mixture is then checked with infrared spectroscopy and no residual isocyanate peak is found indicating the reaction is complete. The mixture is concentrated using a rotavapor. High performance liquid chromatography (HPLC) analysis indicates only one major product. The product is then passed through silica gel chromatography to give final purified product with a yield of at least 80 percent. The product is identified by nuclear magnetic resonance (NMR) and Mass Spectroscopy.
  • EXAMPLE 3 Synthesis of N,N-bis-(2-vinylacetoxyethyl)-(4′-Phenylazo)aniline
  • A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.7 grams (0.02 mole) of N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline and 4.04 grams of triethylamine (0.04 mole). The contents are chilled with an ice bath. Through a dropping funnel, 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes. The ice bath is then removed and the contents are continuously stirred overnight. The mixture is then filtered and then condensed using a rotavapor. HPLC analysis indicates only one major product. The product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent. The product is identified by NMR and Mass Spectroscopy.
  • EXAMPLE 4 Synthesis of N-2-[3′-2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide
  • N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide can be made in two steps. The first step is the formation of 4-vinylacetamidoethyl phenol. The second step is the coupling of azonium salt of toluidine with the phenol to give the product.
  • Step 1. Synthesis of 4-vinylacetamidoethyl phenol.
  • A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.48 grams (0.04 mole) 4-aminoethylphenol and 4.04 grams (0.04 mole) triethylamine. The contents are chilled with an ice bath. Through a dropping funnel, 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes. The ice bath is then removed and the contents are continuously stirred overnight. The mixture is then filtered and then condensed using a rotavapor. High performance liquid chromatography (HPLC) analysis indicates only one major product. The product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent. The product is identified by NMR and Mass Spectroscopy.
  • Step 2. Coupling of product from Step 1 with toluidine diazonium salt.
  • The procedure is about the same as that described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, Example 1, second half. The difference is that 4-vinylacetamidoethyl phenol is used to replace the acrylamidoethyl phenol. The product is identified by NMR and Mass Spectroscopy.
  • EXAMPLE 5 Preparation of Yellow Dye Solution for Coating of an IOL
  • Solutions containing 0.1, 0.5, 1, 2 and 5 weight percent of the yellow dye of Example 4 in methylene chloride are prepared. To these solutions, platinum-cyclovinylmethylsiloxane complex (Gelest, Inc., Tullytown, Pa.) at 1% of the weight of the yellow dye is also added.
  • EXAMPLE 6 Coating of Silicone Intraocular Lenses
  • Ten (10) freshly thermally cured SoFlex™ Model L161 U (Bausch & Lomb, Incorporated, Rochester, N.Y.) lenses are submerged into each coating solution as described in Example 3 for 30, 60 and 120 minutes. The lenses are then removed from the coating solutions and air dried. The lenses are then placed in an oven at 80 to 90° C. for an hour. These lenses are then subjected to standard processing to get the final finished product.
  • Model L161 U lenses are silicone IOLs derived from components consisting of a vinyl terminated polydimethyl-co-diphenyl siloxane, silicon-based reinforcing resins with vinyl groups, and an oligomer with multi hydrosilane units. Model L161 U silicone lenses have excess free hydrosilane groups after curing.
  • EXAMPLE 7 Selection of Yellow Dye Concentration and Coating Conditions
  • Run ultraviolet (UV) and visible absorption spectroscopy of coated lenses before and after processing. Select the yellow dye concentration and residence time of lens in dye solution based on the visible light absorption of the process lenses between 400-500 nm. Conditions, which give about or less than 50% transmittance and maintenance of lens power/cosmetics are chosen for further coating studies, followed by optimization of conditions.
  • Soft, foldable, relatively high refractive index of approximately 1.42 or greater, relatively high elongation of approximately 100 percent or greater, silicone IOLs with blue light absorption properties are synthesized through the process of the present invention. Suitable catalysts for use in the process of the present invention include but are not limited to platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
  • The silicone IOLs produced as described herein have the flexibility required to allow the same to be folded or deformed for insertion into an eye through the smallest possible surgical incision, i.e., 3.5 mm or smaller. It is unexpected that the subject silicone IOLs described herein could possess the ideal physical properties disclosed herein. The ideal physical properties of the subject silicone IOLs are unexpected because changes in mechanical properties such as modulus, percent elongation and tear strength can occur upon addition of the reactive dye functional groups.
  • Silicone IOLs treated using the process of the present invention can be of any design capable of being rolled or folded for implantation through a relatively small surgical incision, i.e., 3.5 mm or less. Such IOLs may be manufactured to have an optic portion and haptic portions made of the same or differing materials. Once the material(s) are selected, the same may be cast in molds of the desired shape, cured and removed from the molds. After such molding, the IOLs are treated in accordance with the process of the present invention and then cleaned, polished, packaged and sterilized by customary methods known to those skilled in the art.
  • In addition to IOLs, the process of the present invention is also suitable for use in the production of other medical or ophthalmic devices such as contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays, corneal rings and like devices.
  • Silicone IOLs manufactured using the process of the present invention are used as customary in the field of ophthalmology. For example, in a surgical cataract procedure, an incision is placed in the cornea of an eye. Through the corneal incision the cataractous natural lens of the eye is removed (aphakic application) and an IOL is inserted into the anterior chamber, posterior chamber or lens capsule of the eye prior to closing the incision. However, the subject ophthalmic devices may likewise be used in accordance with other surgical procedures known to those skilled in the field of ophthalmology.
  • While there is shown and described herein a process for producing silicone IOLs with blue light absorption properties, it will be manifest to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not limited to particular processes and structures herein shown and described except insofar as indicated by the scope of the appended claims.

Claims (18)

1. A method for treating medical devices comprising:
exposing a semi-finished silicone medical device to a solution containing one or more reactive dyes and one or more catalysts.
2. A method for treating medical devices to render said devices capable of absorbing blue light comprising:
exposing a semi-finished silicone medical device to a solution containing one or more reactive dyes and one or more catalysts.
3. The method of claim 1 or 2 wherein said medical device is selected from the group consisting of contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays and corneal rings.
4. The method of claim 1 or 2 wherein said medical device is an intraocular lens.
5. The method of claim 1 or 2 wherein said reactive dyes having ethylenically unsaturated groups are selected from the group consisting of vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene and nitrile.
6. The method of claim 1 or 2 wherein said catalysts are selected from the group consisting of platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
7. The method of claim 1 or 2 wherein said catalysts is a platinum catalyst.
8. The method of claim 1 or 2 wherein said medical device is thermally treated at a temperature less than about 100° C.
9. The method of claim 1 or 2 wherein said medical device is thermally treated at a temperature of about 80 to 90° C.
10. The method of claim 1 or 2 wherein said medical device is thermally treated for about 30 minutes.
11. The method of claim 1 or 2 wherein said medical device is thermally treated for a period of time less than several hours.
12. The method of claim 1 or 2 wherein said medical device is thermally treated for about 120 minutes or less.
13-24. (canceled)
25. A method of using the medical device produced through the method of claim 1 or 2 comprising:
implanting said medical device surgically within an eye.
26. (canceled)
27. The method of claim 1 or 2 wherein said catalyst includes one or more inhibitors.
28. The method of claim 1 or 2 wherein said catalyst includes one or more inhibitors selected from the group consisting of 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane.
29-47. (canceled)
US11/235,441 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties Abandoned US20060020338A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/235,441 US20060020338A1 (en) 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/657,781 US20050055091A1 (en) 2003-09-08 2003-09-08 Process for making silicone intraocular lens with blue light absorption properties
US11/235,441 US20060020338A1 (en) 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/657,781 Division US20050055091A1 (en) 2003-09-08 2003-09-08 Process for making silicone intraocular lens with blue light absorption properties

Publications (1)

Publication Number Publication Date
US20060020338A1 true US20060020338A1 (en) 2006-01-26

Family

ID=34226638

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/657,781 Abandoned US20050055091A1 (en) 2003-09-08 2003-09-08 Process for making silicone intraocular lens with blue light absorption properties
US11/235,497 Expired - Fee Related US7241312B2 (en) 2003-09-08 2005-09-26 Silicone intraocular lens with blue light absorption properties
US11/235,454 Abandoned US20060020340A1 (en) 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties
US11/235,441 Abandoned US20060020338A1 (en) 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US10/657,781 Abandoned US20050055091A1 (en) 2003-09-08 2003-09-08 Process for making silicone intraocular lens with blue light absorption properties
US11/235,497 Expired - Fee Related US7241312B2 (en) 2003-09-08 2005-09-26 Silicone intraocular lens with blue light absorption properties
US11/235,454 Abandoned US20060020340A1 (en) 2003-09-08 2005-09-26 Process for making silicone intraocular lens with blue light absorption properties

Country Status (9)

Country Link
US (4) US20050055091A1 (en)
EP (1) EP1663334A1 (en)
JP (1) JP2007504855A (en)
KR (1) KR20060076291A (en)
CN (1) CN1849146A (en)
AU (1) AU2004271948A1 (en)
CA (1) CA2536730A1 (en)
TW (1) TW200518724A (en)
WO (1) WO2005025632A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070216861A1 (en) * 2006-03-20 2007-09-20 Andrew Ishak Ophthalmic system combining ophthalmic components with blue light wavelength blocking and color-balancing functionalities
US20080043200A1 (en) * 2006-03-20 2008-02-21 Ishak Andrew W Color balanced ophthalmic system with selective light inhibition
US20080090937A1 (en) * 2006-10-13 2008-04-17 Alcon Manufacturing Ltd. Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics
US20080186448A1 (en) * 2006-03-20 2008-08-07 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US20080221674A1 (en) * 2006-03-20 2008-09-11 High Performance Optics, Inc. High performance corneal inlay
US7556376B2 (en) 2006-08-23 2009-07-07 High Performance Optics, Inc. System and method for selective light inhibition
US20100113641A1 (en) * 2008-11-04 2010-05-06 Alcon, Inc. Uv/visible light absorbers for ophthalmic lens materials
US8403478B2 (en) 2001-11-02 2013-03-26 High Performance Optics, Inc. Ophthalmic lens to preserve macular integrity
US8882267B2 (en) 2006-03-20 2014-11-11 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US9377569B2 (en) 2006-03-20 2016-06-28 High Performance Optics, Inc. Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
US9545304B2 (en) 2000-11-03 2017-01-17 High Performance Optics, Inc. Dual-filter ophthalmic lens to reduce risk of macular degeneration
US9683102B2 (en) 2014-05-05 2017-06-20 Frontier Scientific, Inc. Photo-stable and thermally-stable dye compounds for selective blue light filtered optic
US9798163B2 (en) 2013-05-05 2017-10-24 High Performance Optics, Inc. Selective wavelength filtering with reduced overall light transmission
US9927635B2 (en) 2006-03-20 2018-03-27 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6935743B2 (en) 2002-02-06 2005-08-30 John H. Shadduck Adaptive optic lens and method of making
US8361145B2 (en) 2002-12-12 2013-01-29 Powervision, Inc. Accommodating intraocular lens system having circumferential haptic support and method
US7217288B2 (en) 2002-12-12 2007-05-15 Powervision, Inc. Accommodating intraocular lens having peripherally actuated deflectable surface and method
US8328869B2 (en) 2002-12-12 2012-12-11 Powervision, Inc. Accommodating intraocular lenses and methods of use
US10835373B2 (en) 2002-12-12 2020-11-17 Alcon Inc. Accommodating intraocular lenses and methods of use
EP1699385B1 (en) 2003-12-29 2012-10-24 Abbott Medical Optics Inc. Intraocular lenses having a visible light-selective-transmissive-region
JP2007535708A (en) 2004-04-30 2007-12-06 アドバンスト メディカル オプティクス, インコーポレーテッド Ophthalmic device with highly selective purple light transmissive filter
US8133274B2 (en) * 2004-06-18 2012-03-13 Medennium, Inc. Photochromic intraocular lenses and methods of making the same
US20060004165A1 (en) * 2004-06-30 2006-01-05 Phelan John C Silicone hydrogels with lathability at room temperature
US9248614B2 (en) * 2004-06-30 2016-02-02 Novartis Ag Method for lathing silicone hydrogel lenses
US9872763B2 (en) 2004-10-22 2018-01-23 Powervision, Inc. Accommodating intraocular lenses
WO2006057840A2 (en) * 2004-11-22 2006-06-01 Advanced Medical Optics, Inc. Copolymerizable azo compounds and articles containing them
WO2006057824A2 (en) 2004-11-22 2006-06-01 Advanced Medical Optics, Inc. Copolymerizable methine and anthraquinone compounds and articles containing them
WO2007017243A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Silicone hydrogels
WO2007030799A2 (en) 2005-09-08 2007-03-15 Calhoun Vision, Inc. Novel adjustable optical elements with enhanced ultraviolet protection
WO2007068453A2 (en) * 2005-12-14 2007-06-21 Novartis Ag Method for preparing silicone hydrogels
AU2008218313B2 (en) 2007-02-21 2014-01-09 Alcon Inc. Polymeric materials suitable for ophthalmic devices and methods of manufacture
US8968396B2 (en) 2007-07-23 2015-03-03 Powervision, Inc. Intraocular lens delivery systems and methods of use
US8314927B2 (en) 2007-07-23 2012-11-20 Powervision, Inc. Systems and methods for testing intraocular lenses
CA2693906C (en) 2007-07-23 2015-10-06 Powervision, Inc. Post-implant lens power modification
EP2647353B1 (en) 2007-07-23 2014-12-31 PowerVision, Inc. Lens delivery system
US8668734B2 (en) 2010-07-09 2014-03-11 Powervision, Inc. Intraocular lens delivery devices and methods of use
WO2009015226A2 (en) 2007-07-23 2009-01-29 Powervision, Inc. Accommodating intraocular lenses and methods of use
EP2247976B1 (en) * 2008-02-12 2012-08-08 Aaren Scientific Inc. Ophthalmic lens having a yellow dye light blocking component
DE102008063742A1 (en) * 2008-12-18 2010-07-01 *Acri.Tec Gmbh Dye, ophthalmic composition and ophthalmic lens
US10299913B2 (en) 2009-01-09 2019-05-28 Powervision, Inc. Accommodating intraocular lenses and methods of use
JP5894076B2 (en) 2009-08-31 2016-03-23 パワーヴィジョン・インコーポレーテッド Lens capsule size estimation method
KR101069110B1 (en) * 2009-12-04 2011-09-30 손준홍 Accommodative intraocular lens
US8900298B2 (en) 2010-02-23 2014-12-02 Powervision, Inc. Fluid for accommodating intraocular lenses
ES2875049T3 (en) 2011-03-24 2021-11-08 Alcon Inc Intraocular lens loading systems and methods of use
US10433949B2 (en) 2011-11-08 2019-10-08 Powervision, Inc. Accommodating intraocular lenses
EP2967842B1 (en) 2013-03-15 2020-11-04 Alcon Inc. Method of reconfiguring an intraocular lens for delivery to a delivery device
KR101463956B1 (en) * 2013-05-21 2014-11-26 (주)소모옵티칼 Lens For Blocking Blue Light
US9085697B2 (en) 2013-06-21 2015-07-21 Benq Materials Corporation Polymerizable yellow dye for manufacturing ophthalmic lens
WO2017079733A1 (en) 2015-11-06 2017-05-11 Powervision, Inc. Accommodating intraocular lenses and methods of manufacturing
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US20190285912A1 (en) * 2018-03-13 2019-09-19 Eyekeeper Global Inc. Eye Protection Lens
US11543683B2 (en) 2019-08-30 2023-01-03 Johnson & Johnson Vision Care, Inc. Multifocal contact lens displaying improved vision attributes
US11660182B2 (en) 2019-10-04 2023-05-30 Alcon Inc. Adjustable intraocular lenses and methods of post-operatively adjusting intraocular lenses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468229A (en) * 1981-08-12 1984-08-28 Ciba-Geigy Corporation Tinted contact lenses and a method for their preparation with reactive dyes
US6187042B1 (en) * 1998-04-15 2001-02-13 Alcon Laboratories, Inc. Intraocular lens coating compositions
US20030078359A1 (en) * 2001-09-14 2003-04-24 Canon-Staar Co. Inc. Dye for an intraocular lens and an intraocular lens using it

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470932A (en) * 1993-10-18 1995-11-28 Alcon Laboratories, Inc. Polymerizable yellow dyes and their use in opthalmic lenses
JP3928071B2 (en) * 1994-06-30 2007-06-13 スリーエム カンパニー Dental impression materials containing cure-indicating dyes
US6015842A (en) * 1997-08-07 2000-01-18 Alcon Laboratories, Inc. Method of preparing foldable hydrophilic ophthalmic device materials
US5891931A (en) * 1997-08-07 1999-04-06 Alcon Laboratories, Inc. Method of preparing foldable high refractive index acrylic ophthalmic device materials
US6353069B1 (en) * 1998-04-15 2002-03-05 Alcon Manufacturing, Ltd. High refractive index ophthalmic device materials
JP4225612B2 (en) * 1998-09-09 2009-02-18 スター・ジャパン株式会社 Ophthalmic lens material
US6632905B2 (en) * 1999-09-02 2003-10-14 Alcon Universal Ltd. Covalently-bound, hydrophilic coating compositions for surgical implants
US6406739B1 (en) * 2000-01-12 2002-06-18 Alcon Universal Ltd. Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses
WO2002019992A2 (en) * 2000-09-06 2002-03-14 Alcon, Inc. Switchable tackiness coating compositions for ophthalmic implants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468229A (en) * 1981-08-12 1984-08-28 Ciba-Geigy Corporation Tinted contact lenses and a method for their preparation with reactive dyes
US6187042B1 (en) * 1998-04-15 2001-02-13 Alcon Laboratories, Inc. Intraocular lens coating compositions
US20030078359A1 (en) * 2001-09-14 2003-04-24 Canon-Staar Co. Inc. Dye for an intraocular lens and an intraocular lens using it
US6878792B2 (en) * 2001-09-14 2005-04-12 Canon-Staar Co. Inc. Dye for an intraocular lens and an intraocular lens using it
US20050101690A1 (en) * 2001-09-14 2005-05-12 Canon-Staar Co. Inc. Dye for an intraocular lens and an intraocular lens using it

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545304B2 (en) 2000-11-03 2017-01-17 High Performance Optics, Inc. Dual-filter ophthalmic lens to reduce risk of macular degeneration
US8403478B2 (en) 2001-11-02 2013-03-26 High Performance Optics, Inc. Ophthalmic lens to preserve macular integrity
US10610472B2 (en) 2006-03-20 2020-04-07 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US8113651B2 (en) 2006-03-20 2012-02-14 High Performance Optics, Inc. High performance corneal inlay
US20080221674A1 (en) * 2006-03-20 2008-09-11 High Performance Optics, Inc. High performance corneal inlay
US7520608B2 (en) 2006-03-20 2009-04-21 High Performance Optics, Inc. Color balanced ophthalmic system with selective light inhibition
US20070216861A1 (en) * 2006-03-20 2007-09-20 Andrew Ishak Ophthalmic system combining ophthalmic components with blue light wavelength blocking and color-balancing functionalities
US11701315B2 (en) 2006-03-20 2023-07-18 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US9814658B2 (en) 2006-03-20 2017-11-14 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US20080186448A1 (en) * 2006-03-20 2008-08-07 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US10551637B2 (en) 2006-03-20 2020-02-04 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US9927635B2 (en) 2006-03-20 2018-03-27 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US8360574B2 (en) 2006-03-20 2013-01-29 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US11774783B2 (en) 2006-03-20 2023-10-03 High Performance Optics, Inc. High performance selective light wavelength filtering providing improved contrast sensitivity
US8882267B2 (en) 2006-03-20 2014-11-11 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US9063349B2 (en) 2006-03-20 2015-06-23 High Performance Optics, Inc. High performance selective light wavelength filtering
US9377569B2 (en) 2006-03-20 2016-06-28 High Performance Optics, Inc. Photochromic ophthalmic systems that selectively filter specific blue light wavelengths
US20080043200A1 (en) * 2006-03-20 2008-02-21 Ishak Andrew W Color balanced ophthalmic system with selective light inhibition
US7556376B2 (en) 2006-08-23 2009-07-07 High Performance Optics, Inc. System and method for selective light inhibition
US7691918B2 (en) 2006-10-13 2010-04-06 Alcon, Inc. Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics
US20080090937A1 (en) * 2006-10-13 2008-04-17 Alcon Manufacturing Ltd. Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics
US8232326B2 (en) 2008-11-04 2012-07-31 Novartis Ag UV/visible light absorbers for ophthalmic lens materials
US8153703B2 (en) 2008-11-04 2012-04-10 Novartis Ag UV/visible light absorbers for ophthalmic lens materials
US20100113641A1 (en) * 2008-11-04 2010-05-06 Alcon, Inc. Uv/visible light absorbers for ophthalmic lens materials
US9798163B2 (en) 2013-05-05 2017-10-24 High Performance Optics, Inc. Selective wavelength filtering with reduced overall light transmission
US9683102B2 (en) 2014-05-05 2017-06-20 Frontier Scientific, Inc. Photo-stable and thermally-stable dye compounds for selective blue light filtered optic

Also Published As

Publication number Publication date
WO2005025632A1 (en) 2005-03-24
EP1663334A1 (en) 2006-06-07
TW200518724A (en) 2005-06-16
AU2004271948A1 (en) 2005-03-24
US20050055091A1 (en) 2005-03-10
KR20060076291A (en) 2006-07-04
US20060020340A1 (en) 2006-01-26
US20060020337A1 (en) 2006-01-26
JP2007504855A (en) 2007-03-08
CN1849146A (en) 2006-10-18
US7241312B2 (en) 2007-07-10
CA2536730A1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US7241312B2 (en) Silicone intraocular lens with blue light absorption properties
US7304117B2 (en) Reactive yellow dyes useful for ocular devices
US7276544B2 (en) Process for manufacturing intraocular lenses with blue light absorption characteristics
US7033391B2 (en) High refractive index silicone-containing prepolymers with blue light absorption capability
US7198639B2 (en) Polysilsesquioxane containing polymeric compositions
AU2003243507B2 (en) Low water content high refractive index, flexible, polymeric compositions
US6918931B2 (en) Prepolymers with yellow dye moiety

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION